Showing 8,181 - 8,200 results of 100,659 for search '(( 5 we decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 8181
  2. 8182
  3. 8183
  4. 8184
  5. 8185
  6. 8186
  7. 8187
  8. 8188
  9. 8189
  10. 8190
  11. 8191
  12. 8192

    Schematic overview of molecular processes altered during disease progression in the SN of PD, identified using transcriptome analysis. by Anke A. Dijkstra (756877)

    Published 2015
    “…In Braak alpha-synuclein 5 and 6 compared to controls, severe cell loss and alpha-synuclein aggregation is observed [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128651#pone.0128651.ref041" target="_blank">41</a>]. …”
  13. 8193
  14. 8194

    Image_5_Smallholder Coffee in the Global Economy—A Framework to Explore Transformation Alternatives of Traditional Agroforestry for Greater Economic, Ecological, and Livelihood Via... by Pablo Siles (12453132)

    Published 2022
    “…Second, we proposed a framework for multiple benefits quantification converting tree use characteristics and density into five categories of benefits, each with sub-categories which we tested using previously collected data of stem density by species from coffee agroforestry in northern Nicaragua. …”
  15. 8195
  16. 8196
  17. 8197
  18. 8198

    CC genotype of rs7120118 variation associates with decreased soluble Aβ42 levels in the temporal cortex. by Teemu Natunen (398069)

    Published 2013
    “…<p>(A) The distribution of rs7120118 genotypes in subgroups divided by the severity of the disease (mild n = 19/18/9; moderate n = 4/4/5; severe n = 10/12/2, rs7120118 genotypes TT/CT/CC, respectively). …”
  19. 8199

    Data_Sheet_2_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  20. 8200